• NewAmsterdam Pharma flagged new AAIC 2026 presentations on obicetrapib as a potential oral, low-dose approach to early Alzheimer’s prevention.
• Data focus on BROADWAY trial analyses in cardiovascular patients, including P-tau217 predictors, undiagnosed Alzheimer’s pathology, ApoE4-related response, mechanistic pathways.
• AAIC runs July 12-15, 2026 in London; the oral session is scheduled for July 13 at 9:30 AM BST.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewAmsterdam Pharma Company NV published the original content used to generate this news brief on July 01, 2026, and is solely responsible for the information contained therein.